Latex agglutination test kits market to reach $2.13 billion by 2030

The latex agglutination test kits market is projected to grow from $1.59 billion in 2025 to $2.13 billion by 2030, driven by rising infectious disease cases and demand for rapid diagnostics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Latex agglutination test kits are used to detect specific antigens or antibodies in biological samples. - The kits support rapid disease detection in clinical and point-of-care settings. - Faster results can help clinicians start treatment sooner and support outbreak response.

What happened: - The Business Research Company released a report on the global latex agglutination test kits market on Aug. 13, 2026. - The market is projected to grow from $1.59 billion in 2025 to $1.69 billion in 2026. - The report forecasts the market will reach $2.13 billion by 2030. - The report estimates a 6.9% CAGR for the 2025-2026 period and a 5.9% CAGR through 2030. - Download a free sample of the latex agglutination test kits market report. - View the full latex agglutination test kits market report.

The details: - Growth over the past years has been driven by rising infectious disease cases, expanding diagnostic laboratory infrastructure, higher demand for early disease detection, broader use of serological testing and disease-containment strategies. - The report cites increasing need for point-of-care diagnostics, greater emphasis on early disease identification, more investment in diagnostic testing technologies and better access to diagnostics in emerging economies. - The report also points to demand for rapid response tools during outbreaks. - Key trends include rapid testing in clinical environments, wider use of latex agglutination kits for infectious disease detection, routine use in lab diagnostics and preference for affordable, user-friendly diagnostic solutions. - Latex agglutination test kits work through antigen-antibody binding principles. - The kits are described as reliable and versatile for laboratory use. - Rising infectious disease prevalence is a major growth driver. - Infectious diseases are increasing due to globalization, antimicrobial resistance, urbanization, climate change and population growth. - Latex agglutination tests are widely used for rapid detection of bacterial and viral infections. - GOV.UK reported a 10.7% rise in tuberculosis cases in England in February 2024, from 4,380 in 2022 to 4,850 in 2023. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The forecast suggests diagnostic buyers are prioritizing speed, simplicity and lower cost over more complex testing workflows. - Market growth also tracks with wider pressure on health systems to identify infections earlier and respond faster during outbreaks. - Asia-Pacific’s expected growth implies expanding diagnostic capacity in emerging markets could become a major demand center.

What's next: - The market’s pace will likely depend on infectious disease trends, point-of-care adoption and spending on diagnostic technology. - Growth in emerging economies could continue to narrow the gap with established markets such as North America. - The report’s forecast implies steady demand through the end of the decade if rapid testing remains central to clinical workflows.

The bottom line: - Latex agglutination test kits are moving from a niche diagnostic tool to a broader fast-testing category as health systems seek quicker, cheaper ways to identify infections.